Celyad to Participate in Upcoming September 2019 Conferences
August 29, 2019 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights
August 22, 2019 16:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call
August 16, 2019 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors
July 05, 2019 03:21 ET
|
Celyad SA
Preliminary interim results from the alloSHRINK Phase 1 trial demonstrate no evidence of GvHD for first-in-class, non-gene edited allogeneic NKG2D-based CAR-T candidate CYAD-101 when administered...
Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress
July 02, 2019 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, July 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program
July 01, 2019 16:01 ET
|
Celyad SA
Regulators accept proposal to utilize OptimAb manufacturing process, which enriches for T cells with memory-like phenotype, with CYAD-01 under current IND applicationFDA accepts IND application,...
Celyad Presents Clinical Update for CYAD-01 at 24th Congress of the European Hematology Association
June 17, 2019 16:32 ET
|
Celyad SA
Results from the ongoing Phase 1 THINK and DEPLETHINK trials evaluating CYAD-01 for the treatment of relapsed or refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)...
Celyad to Participate in Upcoming June 2019 Conferences
May 29, 2019 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad to Present Data at 24th Congress of the European Hematology Association
May 16, 2019 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 16, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights
May 09, 2019 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 09, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...